Discovery of Pyrano[3,4-b]indoles as Potent and Selective HCV NS5B Polymerase Inhibitors
摘要:
A novel series of HCV NS5B RNA-dependent RNA polymerase inhibitors containing a pyrano-[3,4-b]indole scaffold is described leading to the discovery of compound 16, a highly potent and selective inhibitor that is active in the replicon system.
Discovery of Pyrano[3,4-b]indoles as Potent and Selective HCV NS5B Polymerase Inhibitors
摘要:
A novel series of HCV NS5B RNA-dependent RNA polymerase inhibitors containing a pyrano-[3,4-b]indole scaffold is described leading to the discovery of compound 16, a highly potent and selective inhibitor that is active in the replicon system.
Etodolic acid and related compounds. Chemistry and antiinflammatory actions of some potent di- and trisubstituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids
作者:Christopher A. Demerson、Leslie G. Humber、Adolph H. Philipp、Rene R. Martel
DOI:10.1021/jm00225a010
日期:1976.3
4-b]indole-1-acetic acids bearing one, or two, substituents on the benzene ring has been synthesized via the acid-catalyzed condensation of a substituted tryptophol with ethyl propionylacetate or ethyl butyrylacetate. Antiinflammatory and ulcerogenic effects were examined and the results show that 1, 8-diethyl-1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acid (etodolic acid, USAN) is a potent agent, particularly
一系列在苯环上带有一个或两个取代基的37种1-乙基和1-n-丙基-1,3,4,9-四氢吡喃[3,4-b]吲哚-1-乙酸通过取代的色酚与丙酸乙酯或丁酸乙酯的酸催化缩合反应合成。检查了抗炎和促溃疡作用,结果表明1、8-二乙基-1、3、4、9-四氢吡喃并[3,4-b]吲哚-1-乙酸(依托度酸,USAN)是有效的药物,在慢性大鼠炎症模型(佐剂性关节炎模型中,ED50 0.7 + 1-0.1 mg / kg po)特别有效,并且在同一物种中具有相对较低的急性致溃疡性。
[EN] METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS<br/>[FR] METHODE D'UTILISATION DE DERIVES DU PYRANOINDOLE POUR TRAITER UNE INFECTION PAR LE VIRUS DE L'HEPATITE C
申请人:WYETH CORP
公开号:WO2003099275A1
公开(公告)日:2003-12-04
The invention is directed to methods of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising containing the mammal with an effective amount of a compound of the formula: Wherein substitutions at R1, R2, R3-R12, and Y are set forth in the specification.
[EN] R-ENANTIOMERS OF PYRANOINDOLE DERIVATIVES AGAINST HEPATITIS C<br/>[FR] ENANTIOMERES R DE DERIVES DE PYRANO-INDOLE DIRIGES CONTRE L'HEPATITE C
申请人:WYETH CORP
公开号:WO2003099824A1
公开(公告)日:2003-12-04
The invention is directed to a compound and a pharmaceutical composition of the formula: Wherein substitutions at R1, R2, R3 - R12, and Y are set forth in the specification.
The discovery and structure–activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase
作者:Matthew G. LaPorte、Tandy L. Draper、Lori E. Miller、Charles W. Blackledge、Lara K. Leister、Eugene Amparo、Alison R. Hussey、Dorothy C. Young、Srinivas K. Chunduru、Christopher A. Benetatos、Gerry Rhodes、Ariamala Gopalsamy、Torsten Herbertz、Christopher J. Burns、Stephen M. Condon
DOI:10.1016/j.bmcl.2010.03.002
日期:2010.5
We describe the structure-activity relationship of the C1-group of pyrano[3,4-b]indole based inhibitors of HCV NS5B polymerase. Further exploration of the allosteric binding site led to the discovery of the significantly more potent compound 12. (C) 2010 Elsevier Ltd. All rights reserved.